AMPA receptor inhibitors for the treatment of epilepsy: The role of perampanel

Expert Review of Neurotherapeutics

Volumn 13, Issue 6, 2013, Pages 647-655

  Zaccara, Gaetano ^a   Giovannelli, Fabio ^a   Cincotta, Massimo ^a   Iudice, Alfonso ^b  

^a Florence Health Authority   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

amino 3 hydroxy 5 methyl 4 isoxazolepropionic acid receptors; antiepileptic drugs; drug therapy; epilepsy; partial onset seizures; perampanel

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 3A4; GLUTAMIC ACID; ITRACONAZOLE; LEVODOPA; MIDAZOLAM; OXCARBAZEPINE; PERAMPANEL; TALAMPANEL; TOPIRAMATE;

ADD ON THERAPY; AGGRESSION; AREA UNDER THE CURVE; ATAXIA; BEHAVIOR DISORDER; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; FATIGUE; FIRST PASS EFFECT; FOCAL EPILEPSY; GAIT DISORDER; HEADACHE; HUMAN; IRRITABILITY; MAINTENANCE DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PERSONALITY DISORDER; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; VERTIGO; WEIGHT GAIN;

ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; EPILEPSY; HUMANS; PYRIDONES; RECEPTORS, AMPA;

EID: 84879126684     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.13.46     Document Type: Review

References (39)

1. Kwan P, Brodie MJ. Emerging drugs for epilepsy. Expert Opin. Emerg. Drugs 12(3), 407-422 (2007). (Pubitemid 47518376)
2. Brodie MJ. Antiepileptic drug therapy the story so far. Seizure 19(10), 650-655 (2010).
3. Mula M. GABAergic drugs in the treatment of epilepsy: modern or outmoded? Future Med. Chem. 3(2), 177-182 (2011).
4. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 4(1), 18-61 (2007). (Pubitemid 46107329)
5. Landmark CJ. Targets for antiepileptic drugs in the synapse. Med. Sci. Monit. 13(1), RA1-RA7 (2007). (Pubitemid 46045538)
6. Watkins JC, Jane DE. The glutamate story. Br. J. Pharmacol. 147(Suppl. 1), S100-S108 (2006). (Pubitemid 43077267)
7. Kessels HW, Malinow R. Synaptic AMPA receptor plasticity and behavior. Neuron 61(3), 340-350 (2009).
8. Jane DE, Lodge D, Collingridge GL. Kainate receptors: pharmacology, function and therapeutic potential. Neuropharmacology 56(1), 90-113 (2009).
9. Cokic B, Stein V. Stargazin modulates AMPA receptor antagonism. Neuropharmacology 54(7), 1062-1070 (2008).
10. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 11(2), 56-63 (2011).
11. Ghasemi M, Schachter SC. The NMDA receptor complex as a therapeutic target in epilepsy: a review. Epilepsy Behav. 22(4), 617-640 (2011).
12. De Sarro G, Gitto R, Russo E et al. AMPA receptor antagonists as potential anticonvulsant drugs. Curr. Top. Med. Chem. 5(1), 31-42 (2005). (Pubitemid 40202108)
13. Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol. 7(8), 742-755 (2008). (Pubitemid 351957932)
14. Hanada T, Hashizume Y, Tokuhara N et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 52(7), 1331-1340 (2011).
15. Langan YM, Lucas R, Jewell H et al. Talampanel, a new antiepileptic drug: single-and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia 44(1), 46-53 (2003). (Pubitemid 36733620)
16. Howes JF, Bell C. Talampanel. Neurotherapeutics 4(1), 126-129 (2007). (Pubitemid 46107320)
17. Riva R, Albani F, Ambrosetto G et al. Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects. Epilepsia 25(4), 476-481 (1984). (Pubitemid 14050142)
18. Tothfalusi L, Speidl S, Endrenyi L. Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets. Br. J. Clin. Pharmacol. 65(1), 110-122 (2008). (Pubitemid 350265172)
19. Loscher W, Schmidt D. Epilepsy: perampanel-new promise for refractory epilepsy? Nat. Rev. Neurol. 8(12), 661-662 (2012).
20. Fox SH, Brotchie JM, Lang AE. Nondopaminergic treatments in development for Parkinson's disease. Lancet Neurol. 7(10), 927-938 (2008).
21. Rascol O, Barone P, Behari M et al. Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin. Neuropharmacol. 35(1), 15-20 (2012).
22. Lees A, Fahn S, Eggert KM et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing 'off ' time in Parkinson's disease. Mov. Disord. 27(2), 284-288 (2012).
23. Eggert K, Squillacote D, Barone P et al.; German Competence Network on Parkinson's Disease. Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. Mov. Disord. 25(7), 896-905 (2010).
24. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54(8), 1589-1595 (2000). (Pubitemid 30226801)
25. Marin C, Jimenez A, Bonastre M et al. LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats. Synapse 42(1), 40-47 (2001). (Pubitemid 32786422)
26. Krauss GL, Bar M, Biton V et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol. Scand. 125(1), 8-15 (2012).
27. French JA, Krauss GL, Biton V et al. Adjunctive perampanel for refractory partialonset seizures: randomized Phase III study 304. Neurology 79(6), 589-596 (2012).
28. French JA, Krauss GL, Steinhoff BJ et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global Phase III study 305. Epilepsia 54(1), 117-125 (2013).
29. Krauss GL, Serratosa JM, Villanueva V et al. Randomized Phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 78(18), 1408-1415 (2012).
30. Rektor I, Krauss GL, Bar M et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol. Scand. 126(4), 263-269 (2012).
31. Krauss GL, Perucca E, Ben-Menachem E et al. Perampanel, a selective, noncompetitive a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partialonset seizures: interim results from Phase III, extension study 307. Epilepsia 54(1), 126-134 (2013).
32. Zaccara G, Cincotta M, Borgheresi A, Balestrieri F. Adverse motor effects induced by antiepileptic drugs. Epileptic Disord. 6(3), 153-168 (2004). (Pubitemid 39480678)
33. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 48(7), 1223-1244 (2007). (Pubitemid 47063067)
34. Bannerman DM, Deacon RM, Brady S et al. Cognitive enhancing effects of an AMPA receptor positive modulator on place learning in mice. Behav. Brain Res. 226, 18-25 (2012).
35. Loring DW, Williamson DJ, Meador KJ, Wiegand F, Hulihan J. Topiramate dose effects on cognition: a randomized double-blind study. Neurology 76(2), 131-137 (2011).
36. Ben-Menachem E. Weight issues for people with epilepsy-a review. Epilepsia 48(Suppl. 9), 42-45 (2007). (Pubitemid 350198229)
37. Rektor I. Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures. Expert Opin. Pharmacother. 14(2), 225-235 (2013).
38. Rheims S, Ryvlin P. Retigabine for partial onset seizures. Expert Rev. Neurother. 12(5), 509-517 (2012).
39. Patsalos PN, Berry DJ. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. Expert Opin. Pharmacother. 13(5), 699-715 (2012).